Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Depreciation & Amortization (CF) (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $468000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 8.59% to $468000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, down 1.5% year-over-year, with the annual reading at $2.0 million for FY2025, 1.5% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $468000.0 at Janux Therapeutics, down from $501000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $541000.0 in Q2 2025, with the low at $9000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $349900.0, with a median of $469500.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) surged 2600.0% in 2021, then dropped 8.59% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $64000.0 in 2021, then surged by 529.69% to $403000.0 in 2022, then soared by 31.76% to $531000.0 in 2023, then decreased by 3.58% to $512000.0 in 2024, then decreased by 8.59% to $468000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $468000.0, $501000.0, and $541000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.